Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness

    Access Status
    Fulltext not available
    Authors
    The, I.
    Litton, E.
    Baker, S.
    Erber, W.
    Farmer, Shannon
    Ferrier, J.
    French, C.
    Gummer, J.
    Hawkins, D.
    Higgins, A.
    Hofmann, Axel
    De Keulenaer, B.
    McMorrow, J.
    Olynyk, John
    Richards, T.
    Towler, S.
    Trengove, R.
    Webb, S.
    The, A.
    Date
    2016
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    The, I. and Litton, E. and Baker, S. and Erber, W. and Farmer, S. and Ferrier, J. and French, C. et al. 2016. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness. Intensive Care Medicine. 42 (11): pp. 1715-1722.
    Source Title
    Intensive Care Medicine
    DOI
    10.1007/s00134-016-4465-6
    ISSN
    0342-4642
    School
    Centre for Population Health Research
    URI
    http://hdl.handle.net/20.500.11937/58413
    Collection
    • Curtin Research Publications
    Abstract

    Purpose: Both anaemia and allogenic red blood cell transfusion are common and potentially harmful in patients admitted to the intensive care unit. Whilst intravenous iron may decrease anaemia and RBC transfusion requirement, the safety and efficacy of administering iron intravenously to critically ill patients is uncertain. Methods: The multicentre, randomized, placebo-controlled, blinded Intravenous Iron or Placebo for Anaemia in Intensive Care (IRONMAN) study was designed to test the hypothesis that, in anaemic critically ill patients admitted to the intensive care unit, early administration of intravenous iron, compared with placebo, reduces allogeneic red blood cell transfusion during hospital stay and increases the haemoglobin level at the time of hospital discharge. Results: Of 140 patients enrolled, 70 were assigned to intravenous iron and 70 to placebo. The iron group received 97 red blood cell units versus 136 red blood cell units in the placebo group, yielding an incidence rate ratio of 0.71 [95 % confidence interval (0.43–1.18), P = 0.19]. Overall, median haemoglobin at hospital discharge was significantly higher in the intravenous iron group than in the placebo group [107 (interquartile ratio IQR 97–115) vs. 100 g/L (IQR 89–111), P = 0.02]. There was no significant difference between the groups in any safety outcome. Conclusions: In patients admitted to the intensive care unit who were anaemic, intravenous iron, compared with placebo, did not result in a significant lowering of red blood cell transfusion requirement during hospital stay. Patients who received intravenous iron had a significantly higher haemoglobin concentration at hospital discharge. The trial was registered at http://www.anzctr.org.au as # ACTRN12612001249842.

    Related items

    Showing items related by title, author, creator and subject.

    • Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: A nested cohort study
      Litton, E.; Baker, S.; Erber, W.; Farmer, Shannon; Ferrier, J.; French, C.; Gummer, J.; Hawkins, D.; Higgins, A.; Hofmann, A.; De Keulenaer, B.; McMorrow, J.; Olynyk, John; Richards, T.; Towler, S.; Trengove, R.; Webb, S.; Chapman, A.; Jenkinson, E.; Palermo, A.; Roberts, B. (2018)
      © 2018 The Author(s). Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to ...
    • The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia
      Litton, E.; Baker, S.; Erber, W.; French, C.; Ferrier, J.; Hawkins, D.; Higgins, A.; Hofmann, Axel; De Keulenaer, B.; Farmer, Shannon; McMorrow, J.; Olynyk, John; Richards, T.; Towler, Simon; Webb, S. (2014)
      Background: Allogeneic red blood cell (RBC) transfusion is associated with significant increases in mortality and major morbidity in patients admitted to the intensive care unit, and the blood supplies it requires are an ...
    • Increased hospital costs associated with red blood cell transfusion
      Trentino, K.; Farmer, Shannon; Swain, S.; Burrows, S.; Hofmann, Axel; Ienco, R.; Pavey, W.; Daly, F.; Van Niekerk, A.; Webb, S.; Towler, Simon; Leahy, M. (2015)
      Background - Red blood cell (RBC) transfusion is independently associated in a dose-dependent manner with increased intensive care unit stay, total hospital length of stay, and hospital-acquired complications. Since little ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.